Gyre Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for organ fibrosis and inflammatory diseases, operating through subsidiaries in China and the United States. The company generates revenue from approved anti-fibrotic and hematology products distributed through a single-layer model to hospitals, medical institutions, and pharmacies in China, supported by an in-house sales and marketing team with established relationships with key opinion leaders. Its pipeline includes late-stage candidates targeting liver fibrosis, acute liver failure, pulmonary arterial hypertension, and chronic obstructive pulmonary disease, leveraging specialized infrastructure and deep expertise in fibrosis drug development to expand into adjacent indications and disease areas.